Share
In this poster presented at AACR, the research team describes findings from analyses of EIK1001 pharmacokinetics (PK) and cytokine biomarker data from two Phase 1 clinical trials in participants with advanced solid tumors. PK is linear and dose-proportional. Dose-dependent increases in IP-10 and IFNg are consistent with the TLR7/8 mechanism of action, over a dose range where clinical response was observed in the heavily treated and heterogenous Phase 1 population. These analyses support the design of future clinical trials including dose optimization.
D. Rasco, M. Patel, M. Johnson, A. Tolcher, D. Sommerhalder, O. Hamid, A. Alistar, J. Kochan, E. Kurland, M. Wang, C. Cho, S. Rebello. Pharmacokinetic/biomarker (PK/BMx) analysis of the toll-like receptor 7 and 8 (TLR7/8) agonist EIK1001 in phase 1 studies in participants (Pts) with solid tumors [abstract]. In: Proceedings of the 115th Annual Meeting of the American Association for Cancer Research; 2024 April 5-10; San Diego, CA. Philadelphia (PA): AACR; 2024. Abstract nr 7172. (https://www.abstractsonline.com/pp8/#!/20272/presentation/8036)